Hide

Immunisation Weekly Update:

20190319 Immunisation Needle Icons 31
  1. Measles alert for Sydney
  2. Ensure eligible patients are vaccinated for meningococcal
  3. Qdenga vaccine now available in Australia: Advice for providers
  4. Sydney Local Health District recruiting Authorised Nurse Immunisers
  5. Why is COVID-19 vaccination important for older adults?
  6. Education

People in Sydney are advised to be alert for any signs or symptoms of measles, after NSW Health has put out a measles alert following a confirmed case.

The person visited several locations across Sydney, including Sydney Kingsford Smith International Airport and Canterbury Hospital Emergency Department. The case occurred in a returned traveller from South Asia, where there are ongoing outbreaks of measles.  

Anyone who has attended these locations should monitor for any symptoms.  

Actions for providers: ensure patients are fully vaccinated before travel 

Measles remains one of the most highly contagious vaccine-preventable diseases, with 58 cases confirmed since 1 January 2026. As measles cases continue to be spread by travellers returning from overseas, providers should: 

  • Opportunistically review measles immunity and offer catch-up MMR vaccination where appropriate, particularly in patients planning overseas travel.  
  • Ensure patients born during or after 1966 have documentation of two doses of measles-containing vaccine.  

Who can receive the MMR vaccine?  

NSW provides free measles-mumps-rubella (MMR) vaccine for: 

  • Individuals born during or after 1966 who have not received two documented doses of a measles-containing vaccine. 
  • Individuals with an uncertain measles vaccination history. 
  • Rubella-seronegative postnatal women. 

Following two invasive-meningococcal B (MenB) cases in South Australia in October, and a recent death from the disease, providers are reminded to discuss meningococcal vaccination with eligible patients. 

Those at highest risk of meningococcal infection include infants under 2 years of age, adolescents aged 15-19 years and people in special risk groups. 

Funded vaccines under the National Immunisation Program (NIP) 

  • Meningococcal ACWY Nimenrix® is funded under the NIP for children aged 12 months, adolescents aged 14-16 years and people with certain specific medical risk conditions.  
  • Meningococcal B Bexsero® is funded under the NIP for Aboriginal and Torres Strait Islander infants at 2 months of age (can be given from 6 weeks of age) and for people with medical risk conditions.  

Both MenB and MenACWY vaccines can be given at the same time as other routine childhood vaccines. For further information on funded meningicoccal vaccines, see the National Immunisation Program schedule. For further information on meningococcal disease, see the Australian Immunisation Handbook. 

The dengue vaccine QDenga is now available in Australia for eligible people aged 4 years and over. The Australian Technical Advisory Group on Immunisation (ATAGI) has released interim clinical guidance while a new dengue chapter is being developed for the Australian Immunisation Handbook.  

Qdenga is a live-attenuated vaccine and is contraindicated in people who are pregnant or immunocompromised. It is administered as a 2-dose course, which doses given at least 12 weeks apart.

Who should be considered for Qdenga?  

  • People with a previous dengue infection who are travelling to dengue-endemic areas, regardless of travel duration.  
  • People without previous dengue infection who are planning long-term or repeated travel to dengue-endemic areas.  
  • People with potential occupational exposure to dengue virus, such as laboratory workers. 

Qdenga may also be considered for some travellers undertaking shorter-term travel to dengue-endemic areas following an individual risk assessment. Providers seeking information on vaccine availability should contact their private vaccine supplier. 

Recent update to ATAGI’s clinical advice 

The clinical advice statement from the ATAGI has had a minor update. While pregnant individuals are not recommended to receive Qdenga, vaccination may be considered if travel to a country with dengue virus is unavoidable, following an individual risk-benefit assessment.  

For detailed recommendations refer to the ATAGI clinical advice statement. 

The Sydney Local Health District Public Health Unit is currently seeking Authorised Nurse Immunisers (ANIs) to join their casual pool staff, school immunisation workforce.

To learn more about the role and to apply, visit the career portals below:

Applications close on the 25 November 2026 at 11:59pm.

The National Centre for Immunisation Research and Surveillance Australia (NCIRS) has released an information guide to support COVID-19 vaccination in older adults. 

The resource highlights the ongoing impact of COVID-19 in older age groups, the benefits of staying up to date with recommended vaccine doses, and current vaccination recommendations.  

The resource also provides evidence demonstrating lower rates of COVID-19 related death among people who have received a recent COVID-19 vaccine dose, compared to people who received a vaccine more than 12 months ago, and reinforces that COVID-19 vaccines can be administered at the same time as other vaccines, including influenza vaccine.  

Providers are encouraged to share this resource with eligible patients and their carers.  

Online CPD course  Immunisation Coalition: Influenza vaccination in children and adolescents
 
The latest information, practice tips, patient cases and consultation examples.  

Take course here   
Wednesday 25 November 2026  6:00-7:00pm AEDT 
  
 
 
Immunisation Coalition: Shingles Webinar  

This webinar provides viewers an update regarding epidemiology, eligibility criteria including immunocompromised individuals and risk categories, disease burden, safety, co-administration opportunities, and current trends in vaccination rates. 

Speaker: A/Prof John Litt 
Moderator: Dr Andrew Minton, PHD 

Register Here  
Tuesday 1 December 2026  12:00-1:00pm AEDT     What’s new in travel vaccination – dengue, rabies and measles 

Join the NCIRS and expert presenters for a webinar exploring new and emerging issues in travel vaccination. The webinar will cover Australia’s first dengue vaccine, changes to rabies post-exposure vaccination guidance, counterfeit rabies vaccines, increasing measles activity and susceptibility, recommendations for measles vaccination and case studies to support administering travel vaccines. 

The webinar will conclude with a Q&A panel.  

Register here.  
Sunday 14 February 2027: 3:00pm-8:20pm
Monday 15 February 2027: 9:00am-4:15pm    
28th Annual Scientific Meeting 

The Immunisation Coalition has announced the dates and topics for the 28th Annual Scientific Meeting. For further information on the topics currently included visit 28th Annual Scientific Meeting – Immunisation Coalition.

Location: Pullman Melbourne Albert Park, 65 Queens Rd, Albert Park, VIC, 3004

Register onsite or online here.

CESPHN
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.